WebMay 22, 2024 · On May 6, Galecto announced that it had recruited more than 150 patients to date for its Phase IIb GALACTIC-1 study of GB0139 (formerly TD139) for idiopathic pulmonary fibrosis (IPF). GP0139 is an inhaled galectin-3 inhibitor. The company stated that its ability to recruit, especially in areas that have been most affected by Covid-19, namely ... WebApr 26, 2024 · GALACTIC-1 is a randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 2b study being conducted across approximately 100 centers …
U.S. leaks show clash between
WebJan 14, 2024 · To the Editor: In their phase 3 trial, Global Approach to Lowering Adverse Cardiac Outcomes through Improving Contractility in Heart Failure (GALACTIC-HF), … WebNov 12, 2024 · Patients with heart failure and a reduced ejection fraction who received the selective cardiac myosin activator omecamtiv mecarbil had a lower risk of a composite of heart failure events and cardiovascular death than those who received placebo, according to results from the GALACTIC-HF trial presented Nov. 13 during AHA 2024 and … chocolate sarayi ghana
Vericiguat in Patients with Heart Failure and …
WebMay 12, 2024 · The novel selective cardiac myosin activator omecamtiv mecarbil produced a greater reduction in heart failure (HF) events in at-risk patients with lower baseline ejection fractions (EF), according to results of a new analysis from the GALACTIC-HF trial presented May 17 during ACC.21 and simultaneously published in the Journal of the … WebFeb 6, 2024 · GALACTIC-1 -A Randomized, Double-blind, Multicentre, Parallel, Placebo-controlled Phase 2b Study in Subjects With Idiopathic Pulmonary Fibrosis (IPF) … WebJul 13, 2024 · GALACTIC-1 is a 52-week randomized, double-blind, multicenter, parallel, placebo-controlled Phase 2b trial being conducted across more than 100 centers … chocolate sarayi kinshasa